Oncolytics Biotech Inc
$ 0.80
0.24%
07 Aug - close price
- Market Cap 95,555,000 USD
- Current Price $ 0.80
- High / Low $ 0.82 / 0.79
- Stock P/E N/A
- Book Value -0.04
- EPS -0.32
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.88 %
- ROE -7.69 %
- 52 Week High 1.51
- 52 Week Low 0.73
About
Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. The company is headquartered in Calgary, Canada.
Analyst Target Price
$5.08
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-30 | 2025-11-12 | 2025-08-08 | 2025-05-14 | 2025-03-07 | 2024-11-12 | 2024-08-01 | 2024-05-09 | 2024-03-07 | 2023-11-03 | 2023-08-14 |
| Reported EPS | -0.11 | 0 | -0.14 | -0.07 | -0.08 | -0.1 | -0.12 | -0.1 | -0.09 | -0.05 | -0.13 | -0.11 |
| Estimated EPS | -0.07 | -0.075 | -0.07 | -0.08 | -0.09 | -0.13 | -0.11 | -0.11 | -0.11 | -0.15 | -0.11 | -0.11 |
| Surprise | -0.04 | 0.075 | -0.07 | 0.01 | 0.01 | 0.03 | -0.01 | 0.01 | 0.02 | 0.1 | -0.02 | 0 |
| Surprise Percentage | -57.1429% | 100% | -100% | 12.5% | 11.1111% | 23.0769% | -9.0909% | 9.0909% | 18.1818% | 66.6667% | -18.1818% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ONCY
2026-08-07 05:40:17
Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the stock currently holds a "Moderate Buy" consensus rating with an average target price of $8.50.
2026-08-02 03:41:05
This article provides the 10-Q report for Oncolytics Biotech for the first quarter of 2026. The content is a placeholder, indicating that the full financial document is intended to be included.
2026-08-01 05:10:29
This article provides a financial health analysis of Oncolytics Biotech Inc (ONCY), stating its current financial score is 6.34 and ranks 258 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is considered stable, though its operating efficiency is low. Key financial metrics such as cash and cash equivalents, total assets, and operating profit have not yet been disclosed by the company.
2026-07-28 14:11:25
This article provides a comprehensive stock analysis of Oncolytics Biotech Inc (ONCY), highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from multiple analysts despite a recent weak stock market performance. The company is developing pelareorep, an immunotherapeutic agent for various cancers, and is advancing clinical studies for breast cancer and pancreatic cancer. The analysis uses TradingKey's stock score, which evaluates financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment.
2026-07-27 23:31:36
This article provides a revenue breakdown for Oncolytics Biotech Inc (ONCY). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page presents general stock information for ONCY, including its market cap and recent price movements.
2026-07-27 11:42:41
Oncolytics Biotech Inc. (ONCY) was granted FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor for 2L+ squamous cell anal cancer, based on promising results from the GOBLET study. Despite this positive development, the company received a Nasdaq compliance notice for its stock falling below $1.00 and has until January 19, 2027, to regain compliance.
